Summary. Frangakis and Rubin (2002, Biometrics 58, 21-29) proposed a new definition of a surrogate endpoint (a "principal" surrogate) based on causal effects. We introduce an estimand for evaluating a principal surrogate, the causal effect predictiveness (CEP) surface, which quantifies how well causal treatment effects on the biomarker predict causal treatment effects on the clinical endpoint. Although the CEP surface is not identifiable due to missing potential outcomes, it can be identified by incorporating a baseline covariate(s) that predicts the biomarker. Given case-cohort sampling of such a baseline predictor and the biomarker in a large blinded randomized clinical trial, we develop an estimated likelihood method for estimating the CEP surface. This estimation assesses the "surrogate value" of the biomarker for reliably predicting clinical treatment effects for the same or similar setting as the trial. A CEP surface plot provides a way to compare the surrogate value of multiple biomarkers. The approach is illustrated by the problem of assessing an immune response to a vaccine as a surrogate endpoint for infection.
Introduction
Identifying biomarkers that can be used as approximate surrogates for clinical endpoints in randomized trials is useful for many reasons including shortening studies, reducing costs, sparing study participants discomfort, and elucidating treatment effect mechanisms. As a motivating example, a central objective of placebo-controlled preventive HIV vaccine efficacy trials is the evaluation of vaccine-induced immune responses as surrogate endpoints for HIV infection. An immunological surrogate would be useful for several purposes including guiding iterative development of immunogens between basic and clinical research, informing regulatory decisions and immunization policies, and bridging efficacy of a vaccine observed in a trial to a new setting.
The surrogate evaluation field was catalyzed by Prentice's (1989) definition of a surrogate endpoint as a replacement endpoint that provides a valid test of the null hypothesis of no treatment effect on the clinical endpoint. The two main criteria for checking this definition are: (i) the distribution of the clinical endpoint conditional on the surrogate is the same as the distribution of the clinical endpoint conditional on the surrogate and treatment (i.e., all of the clinical treatment effect is "mediated" through the surrogate); and (ii) the surrogate and clinical endpoints are correlated. Frangakis and Rubin (2002) (henceforth FR) noted that this definition is based on observable random variables, and named a biomarker satisfying criterion (i) a "statistical surrogate." Since 1989, many surrogate-evaluation methods have been designed to check if a biomarker is a statistical surrogate, including methods for estimating the proportion of the treatment effect explained (Freedman, Graubard, and Schatzkin, 1992) . Notably some approaches have not been based on (i); for example, the adjusted association estimand is designed for evaluating the correlation criterion (ii), and the relative effect estimand is based on average causal effects (Buyse and Molenberghs, 1998) .
Treatment effects adjusted for a variable measured after randomization (called net effects) are susceptible to postrandomization selection bias. Because candidate surrogates are measured after randomization, criterion (i) defining a statistical surrogate is based on net effects. FR pointed out that this definition does not have a causal interpretation, and proposed a new surrogate definition based on principal causal effects. FR's definition of a "principal surrogate" is based on the potential outcomes framework for causal inference, which Robins (1995) also considered for studying treatment effects subject to postrandomization selection bias. To date, statistical methods for evaluating principal surrogates have not been elaborated. A recent review paper noted that FR "present a convincing case for the principal surrogate definition" and called for such elaborations (Weir and Walley, 2006) .
The literature on statistical methods for evaluating surrogate endpoints contains approaches based on a single large clinical trial and on metaanalysis. Here we develop an approach for evaluating a principal surrogate within the former setting. Following Follmann (2006) , our approach uses a baseline covariate(s) to predict missing potential biomarker outcomes. After defining statistical and principal surrogates in Section 2, in Section 3 we introduce the causal effect predictiveness (CEP) surface and the marginal CEP curve, plus associated summary causal estimands, which quantify how well a biomarker predicts population-level causal effects of treatment. In Section 4, we develop an estimated-likelihood approach for estimating the causal estimands based on casecohort sampling of the biomarker, and parametric or nonparametric marginal structural mean models. In Section 5, we evaluate the nonparametric method in simulations based on an HIV vaccine trial, and in Section 6 we conclude with discussion.
Statistical and Principal Surrogates
Throughout we consider a randomized trial with treatment assignment Z (Z = 1 or 0), a discrete or continuous biomarker S measured at fixed time t 0 after treatment assignment, and a binary clinical endpoint Y (Y = 1 for disease, 0 otherwise) measured after t 0 . Because S must be measured prior to disease to evaluate it as a candidate surrogate, the analysis is restricted to subjects disease free at t 0 ; denote this evaluability criterion by the indicator V = 1. The biomarker S is only measured in those with V = 1, and otherwise is undefined (denoted by S = * ). We consider two phase outcomedependent case-cohort sampling, wherein baseline covariates X are measured for everyone (phase 1) and in the second phase a baseline covariate(s) W is measured for all or almost all cases (those with Y = 1) and for a random "subcohort" of controls (those with Y = 0). Let δ indicate whether W is measured. For subjects with V = 1, S is measured for those with W measured. Case-cohort sampling is efficient when W or S is expensive (Prentice, 1986) . For vaccine trials, W and S can be measured after the trial using stored specimens (Gilbert et al., 2005) .
Definition of a Statistical Surrogate
Following FR, methods for evaluating statistical surrogates are based on comparing the risk distributions
If S is continuous then these definitions abuse notation; however, to avoid the distraction of technical details the formal definitions are placed in Web Appendix A. FR defined S to be a statistical surrogate if, for all values s of S, risk(s | Z = 1) = risk(s | Z = 0).
Because S and V are measured after randomization, a comparison of risk(s | Z = 1) and risk(s | Z = 0) measures the net effect of treatment, i.e., differences due to a mixture of the causal treatment effect and any differences in characteristics between treatment 1 subjects who have response level s, {Z = 1, V = 1, S = s}, and treatment 0 subjects who have response level s, {Z = 0, V = 1, S = s}. Consequently, application of a method that evaluates a statistical surrogate may mislead about the capacity of a biomarker to reliably predict causal clinical treatment effects.
Definition of a Principal Surrogate Endpoint
Let Y(Z) be the potential clinical endpoint after time t 0 under assignment to treatment Z. Similarly define potential outcomes S(Z) for the biomarker endpoint measured at t 0 , and let V(Z) be the potential indicators of whether the subject is disease free at t 0 , for Z = 0,1. Note that S(Z) and (Rubin, 1986) : Conditional on X, Z is independent of (W , V (1), V (0), )) are independent of the treatment assignments of other subjects, which implies "consistency,"
. A2 holds for blinded randomized trials, where the randomization may depend on X. A3 will be needed for identifying the causal estimand based on data from subjects observed to be at risk for disease at t 0 . Inferences will be robust to A3 if t 0 is near baseline relative to the period of follow-up for clinical events and the vast majority of subjects are at risk at t 0 , in which case
With these preliminaries, we now define a principal surrogate endpoint. FR defined the basic principal stratification P 0 with respect to the postrandomization variable S as the partition of units i = 1, . . . , n such that within any set of P 0 , all units have the same vector (S i (1), S i (0)). A principal stratification is a partition of units whose sets are unions of sets in P 0 . FR defined a biomarker S to be a principal surrogate endpoint if the comparison between
results in equality for all s 1 = s 0 . FR did not explicitly condition on V (1) = V (0) = 1 in their definition; however, implicitly they must have, because (S(1), S(0)) is only defined if V (1) = V (0) = 1. For notational simplicity henceforth all probability statements involving S(Z) implicitly condition on V (Z) = 1. A contrast in risk (1) (s 1 , s 0 ) and risk (0) (s 1 , s 0 ) measures a population-level causal treatment effect on Y for subjects with {S i (1) = s 1 , S i (0) = s 0 }. Such a contrast is causal because it conditions on a principal stratification, which, by construction, is unaffected by treatment. Thus in FR's definition, S is a principal surrogate if groups of subjects with no causal effect on the biomarker have no causal effect on the clinical endpoint. We call this property average causal necessity.
Average causal necessity:
Biomarkers with the greatest utility for predicting clinical treatment effects will not only be necessary for a clinical effect, but also sufficient. For example, knowing that an antibody titer > 1000 is sufficient for a vaccine to protect individuals against HIV infection is exactly the information needed to use titer as a reliable predictor of protection. We define average causal sufficiency as Average causal sufficiency: There exists a constant
For the one-sided situation where interest is in assessing if higher treatment 1 biomarker responses (S(1) > S(0)) predict clinical benefit of treatment 1 (Y (1) = 0 and Y (0) = 1) (e.g., a placebo-controlled trial), a one-sided version of average causal sufficiency may be more appropriate, defined as above with = replaced with < and |s 1 − s 0 | replaced with s 1 − s 0 . In either case, we suggest a refined definition of a principal surrogate endpoint as a biomarker that satisfies both average causal necessity and average causal sufficiency. Henceforth we use this definition of a principal surrogate endpoint.
Causal Effect Predictiveness Estimands

Quantitation of Associative and Dissociative Effects
FR suggested that the quality of a surrogate be measured by its "associative effects" relative to its "dissociative effects." As defined in equations 5.3 and 5.4 of FR, an associative effect is a comparison between the ordered sets
and a dissociative effect is a comparison between the ordered sets
For the purpose of quantifying these effects, we introduce a causal effect predictiveness (CEP) surface. Let CE ≡ h(Pr(Y (1) = 1), Pr(Y (0) = 1)) be the overall causal effect of treatment on the clinical endpoint, where h(·, ·) is a known contrast function satisfying h(x, y) = 0 if and only if x = y, for example h(x, y) = x − y or log(x/y). Let
for all s is equivalent to average causal necessity, whereas CEP risk (s 1 , s 0 ) = 0 for all |s 1 − s 0 | > C (or the one-sided analog) is equivalent to average causal sufficiency. Therefore, the criteria for a principal surrogate can be checked through inference on the CEP surface. Moreover, biomarkers with capacity to predict clinical treatment effects will often have |CEP risk (s 1 , s 0 )| increasing in |s 1 − s 0 |, reflecting the situation that on average groups of persons with a greater causal effect on the marker have a greater causal effect on the clinical endpoint. We refer to the capacity of a biomarker to reliably predict the population level causal effect of treatment on the clinical endpoint as the biomarkers' surrogate value. This value can be quantified both by the nearness of |CEP Huang, Pepe, and Feng's (2007) proposal to judge the value of a continuous marker S for predicting disease Y by the predictiveness curve, (v) is risk as a function of the quantiles of S, which provides a common scale for comparing multiple markers. The predictiveness curve R(v) usefully informs about both absolute risks at different marker quantiles and the frequency of these risks in the population. A predictive marker is one with
Applying these ideas, we propose a scale-independent version of the causal effect predictiveness surface,
(1) (v 1 ),
In this definition, S(1) and S(0) are standardized relative to the distribution F (1) of S(1). Figure 1 illustrates two CEP surfaces for the one-sided setting where interest is in predicting clinical benefit of treatment 1 from higher treatment 1 biomarker responses. For some studies, the marginal CEP curve is a related causal estimand of interest: If S i (0) is constant across subjects, then the CEP surface (trivially) equals the marginal CEP curve. We refer to this special case as case CB:
Case CB. Constant Biomarkers: S i (0) = c for all i for some constant c HIV vaccine trials fit case CB, with (almost) all subjects having no immune response under placebo (Z = 0). This occurs because S is an HIV-specific immune response, so that vaccine antigens must be presented to the immune system to induce a response (Gilbert et al., 2005 (Figure 2) .
For placebo-controlled trials for which case CB fails yet S i (0) has much less variability than S i (1), the marginal CEP curve has interpretation approximately equal to that of CEP(s 1 , s 0 ). In general, however, mCEP(s 1 ) does not measure the association between causal biomarker effects and causal (ii) High surrogate value
The surface in (i) reflects a biomarker with no surrogate value, wherein the clinical treatment effect is the same for all treatment effects on the biomarker. The surface in (ii) reflects a biomarker with high surrogate value, wherein the average causal effect on the clinical endpoint is zero for v 1 = v 0 and has a large increase in 
risk (c, c) = 0 and CEP risk (s 1 , c) > 0 for all s 1 > c, the latter two S's satisfy average causal necessity and average causal sufficiency, and hence are principal surrogates. This figure appears in color in the electronic version of this article.
clinical effects, and hence does not measure principal surrogate value. Nevertheless, under A1 and A2 mCEP(s 1 ) has a different but useful interpretation as the population level causal treatment effect on Y for subjects with S(1) = s 1 , where conditioning on S(1) is equivalent to conditioning on a baseline covariate. As such, the marginal CEP curve can be used for predicting how clinical efficacy varies with the biomarker S = S(1) observed in persons attending a treatment or vaccine clinic.
Estimands for Summarizing Surrogate Value
We suggest functionals of the CEP surface that summarize the surrogate value of a biomarker. We again consider the one-sided setting where interest is in assessing whether S(1) > S(0) predicts clinical benefit of treatment 1 (Y (1) = 0 and Y (0) = 1). To summarize the associative and dissociative effects, we consider the expected associative effect (EAE) and the expected dissociative effect (EDE):
where ω(·, ·) is a nonnegative weight function. For case CB with c = L,
We also define the proportion associative (PA) effect by 
If h(x, y) = x − y, Pr(S(1) > S(0)) = 0.5, and an additional monotonicity assumption is made (that Y i (1) ≤ Y i (0) for all i, i.e., no one is harmed by treatment 1), then PAE ω=1 equals the PA, defined by
(proof in Web Appendix A). This summary measure, proposed by Taylor, Wang, and Thiebaut (2005) , is interpreted as the proportion of the study population with a beneficial causal clinical effect that also has a positive causal surrogate effect. The PA depends on the underlying principal strata distribution )) is small (large) then the PA will tend to be small (large), irrespective of the biomarker's surrogate value. By conditioning on (S(1), S(0)), the PAE ω is designed to be robust to F (1),(0) (·, ·); the PAE ω reflects the relative magnitude of clinical effects for those with and without surrogate effects.
Biomarkers satisfying average causal necessity have EDE = 0 and thus PAE ω = 1, in which case EAE ω contributes no information to the PAE ω . Therefore, additional measures are needed for summarizing the magnitude of associative effects. One such measure is the associative span (AS), defined by
and AS. Although the summary parameters may be useful, it is important to estimate the CEP estimands over the range of marker values or quantiles to provide a full picture of the associative and dissociative effects. Below we also consider estimands defined as above except they condition on X and/or W; for example risk (Z) x, w) ). The conditional estimands reflect baseline covariatespecific surrogate value.
Estimating the CEP Surface and Marginal
CEP Curve We consider one approach to identifying and estimating the CEP surface in the practically important special case CB. The same approach identifies and estimates the marginal CEP curve in the general case that S i (0) has arbitrary variability. In case CB it is difficult to evaluate a statistical surrogate, because it is not possible to study the correlation of S with Y in arm Z = 0 subjects, and it is conceptually difficult to evaluate whether S fully mediates clinical treatment effects (Chan et al., 2002) .
Identifiability of the Causal Estimands
Due to missing potential outcomes the CEP surface and marginal CEP curve are not identified without further assumptions. A1-A3 imply
demonstrating that risk (Z) (s 1 , s 0 , x, w) would be identified if we knew the potential outcomes S i (Z) of subjects assigned the opposite treatment 1 − Z. Estimating the CEP surface will therefore require a way to predict the missing potential biomarkers. This challenge is relatively easy in case CB, for which risk (1) (s 1 , c, x, w) is identified by the observed data in arm Z = 1. However, A1-A3 do not identify risk (0) (s 1 , c, x, w), and the remaining task to identify the CEP surface entails determining values S i (1) for arm Z i = 0 subjects.
Baseline Predictor Study Design and Likelihood
Our method of inference is based on one of the augmented vaccine trial designs proposed by Follmann (2006) , wherein a baseline covariate(s) W that is predictive of S(1) is measured in subjects in both treatment arms. A model predicting S(1) from X and W fit from arm Z = 1 subjects is used to predict S(1) for arm Z = 0 subjects. The predictions are unbiased because A1-A3 imply S(1)
Only subjects with V i = 1 contribute to the likelihood. Subjects with
is modeled as a function of unknown parameters β. The likelihood contribution for subjects with
The contribution for subjects with δ i = 0 is obtained by integrating risk
,
.
Because CEP risk (·, c, X, W ; β) depends on β but not ν, the ν are nuisance parameters. Although profile likelihood is a natural approach to pursue, it is difficult to implement because the likelihood integrates over F S|X,W (1) and F W |X . We use estimated likelihood (Pepe and Fleming, 1991) , also called pseudolikelihood, wherein consistent estimates of ν are obtained based on treatment arm 1 data, and then L(β,ν) is maximized in β. The bootstrap is used to estimate standard errors forβ. A re-sampling approach is used because there does not appear to be an analytical expression for the asymptotic variance ofβ that accounts for the variations inν, and previously developed techniques for deriving the variance do not apply because they would assume that all subjects have a non-zero probability that S(1) is observed (e.g., Pepe and Fleming, 1991) .
Models for Risk
The estimated likelihood approach can be used for a variety of structural models for risk (z) (s 1 , c, x, w) and the nuisance parameters ν. Here we consider two types of models for case CB. The first is fully parametric, where we assume F
S|X,W
and F W |X have particular parametric distributions, and S(1) is continuous subject to "limit of detection" left-censoring: S(1) ≡ max(S * (1), c), where S * (1) has a continuous cdf with Pr(S * (1) ≤ c) > 0. We also assume the risk functions have a generalized linear model form 
is censored normal, with left-censoring of values below c, and A4-P holds with g equal to the standard normal cdf Φ. This set-up extends Follmann (2006) to account for censoring. With h(x, y) = g −1 (x) − g −1 (y), A4-P then implies CEP risk (s 1 , c, x, w; β) = (β 10 − β 00 ) + (β 11 − β 01 )s 1
Simple calculations yield EDE(x, w) = (β 10 − β 00 ) + ( Secondly, we consider a nonparametric approach wherein S and W are treated as categorical variables with J and K levels, which may be discretized versions of continuous measurements. Here we assume the lowest category j = 1 corresponds to the constant c in case CB. With W the only baseline covariate, nonparametric models are specified by ν jk ≡ Pr(S(1) = j, W = k) and
β k = 0 for identifiability. Under model A4-NP, W has the same effect on risk for the two study arms. This no-interaction assumption identifies the model, and the expanded model with β k replaced with β zk is not identified (see Web Appendix C).
In the simulations we consider the CEP curve estimand CEP risk (j, 1; β) = log(risk (1) (j, 1; β 1j )/risk (0) (j, 1; β 0j )) based on average risks risk (z) (j, 1; 
Tests for Whether a Biomarker Has Any Surrogate Value
Because PAE ω = 0.5 supports that S has no surrogate value, Wald tests for any surrogate value can be based on the maximum estimated likelihood estimator (MELE) PAE ω minus 0.5 divided by its bootstrap standard error. Similarly Wald tests of AS = 0 can be implemented based on AS. For the nonparametric approach assuming model A4-NP, we also consider a test statistic T = J j=2 (j − 1){β 0j − (β 0j +β 1j )(μ 0 / (μ 0 +μ 1 ))} divided by its bootstrap standard error, wherê
for all j versus the monotone alternative that CEP risk (j, 1) increases in j, similar to the Breslow-Day trend test (Breslow and Day, 1980) . The null and alternative hypotheses indicate that average causal sufficiency does not and does hold, respectively.
Simulation Study
Based on data from the first preventive HIV vaccine efficacy trial (Gilbert et al., 2005) , we conducted a simulation study to evaluate performance of the MELE methods. The vaccine trial was double blind with 2:1 randomization to vaccine:placebo. A biomarker of interest S was the 50% neutralization titers against the HIV recombinant gp120 molecule measured from a serum sample drawn at the month 1.5 visit, and Y was HIV infection during the time period t 0 = 1.5 months to 36 months. The lower quantification limit of the neutralization assay was 1.65, and 44 of 47 placebo recipients with S measured at 1.5 months had left-censored values; thus the data essentially fit case CB. The range of S i was [1.65, 4.09], which we rescaled to [0, 1] , so that c = L = 0.
We simulated vaccine trials with the following steps.
Step 1: For all 3598 (1805) subjects in the vaccine (placebo) arm, (W i , S i (1)) was generated from a bivariate normal distribution with means 0.41, standard deviation 0.55, and correlation ρ = 0.5, 0.7, or 0.9; the standard deviation was chosen such that 23% of S i (1) values were less than 0 on average. Simulated values of S i (1) and W less than 0 (greater than 1) were set equal to 0 (1).
Step 2: The W i and S i (1) were binned into quartiles. For subjects i with quartile j value of S i (1) and quartile k value of W i , Y i (Z) was generated from a Bernoulli distribution with success probability determined by model A4-NP with values of β zj and β k set as follows. First, the β zj were set to achieve the infection rate Pr(Y (1) = 1) = 0.067 that was observed in the vaccine arm of the trial, an overall vaccine efficacy of 50% (i.e., Pr(Y (0) = 1) = 2 × Pr(Y (1) = 1)) and to reflect a biomarker with either (i) no or (ii) high surrogate value. Based on risk averaged over W described in Section 4.3, in scenario (i) Step 3: To achieve casecohort sampling, (W i , S i (1)) was retained for all infected vaccine recipients and a subcohort of uninfected vaccine recipients. For the placebo arm S i (1) was set to missing for everyone and W i was retained only for all infected placebo recipients and for a subcohort of uninfected placebo recipients. For each arm, the ratio of controls to cases was 3:1. The simulated data sets satisfied A1-A3 and A4-NP.
For each of 1000 simulated data sets the MELEβ was computed using the nonparametric approach described in Section 4.3. Then, with h(x, y) = log(x/y),β was used to compute the MELEs of CEP risk (j; 1), AS, and PAE ω for ω(j; 1) = 1, j, and I(j = J = 4). Wald tests (with bootstrap standard errors) based on PAE ω − 0.5, AS, and T were used to test for any surrogate value. The MELEs of CEP risk (j; 1), PAE ω and AS performed well (Tables 1 and 2 ). Bootstrap percentile confidence intervals (CIs) had approximately nominal coverage and for higher values of ρ the MELEs exhibited negligible bias. The tests for any surrogate value had approximately nominal size and showed adequate power to detect surrogate value; the nonparametric trend test had power 0.83, 0.99, and >0.99 for ρ = 0.5, 0.7, and 0.9 under scenario (ii). Additional simulations were conducted to evaluate the performance of the MELE method with binned covariates when the data were generated from a continuous model. Specifically, Step 2 described above was replaced with Step 2 : For vaccine arm subjects, Y i (1) was generated using model A4-P with g = Φ and (β 10 , β 11 , β 12 , β 13 ) = (−1.21, −0.67, 0, −0.1) set to fit the real vaccine arm data with infection rate 0.067. For the placebo arm, we supposed overall vaccine efficacy of 50% and generated Y i (0) assuming model A4-P with β 02 = 0, β 03 = β 13 and either (i) (Table 3 ). Relative to Table 2 , there was a slight increase in bias and in standard errors. Tests for any surrogate value had approximately nominal size, with power only slightly lower than in the previous set of simulations. and AS. SEE is the median of the bootstrap standard error estimates based on 500 bootstrap replicates. CP is the empirical coverage of bootstrap percentile 95% confidence intervals for PAE ω and AS. Power is for one-sided tests of H 0 : PAE ω = 0.5 versus H 1 : PAE ω > 0.5 or H 0 : AS = 0 versus H 1 : AS >0 at level α = 0.05. For the PAE weights, ω 1 (j, 1) = 1, ω 2 (j, 1) = j, and ω 3 (j, 1) = I[j = J = 4]. A total of 1000 simulations were done to compute the table elements for each model. These simulation studies provide a "proof of principle" that the proposed methods can reliably estimate the CEP surface and distinguish biomarkers with no or high surrogate value.
Discussion
A main use of a surrogate endpoint is predicting treatment effects on a clinical endpoint. Within the principal surrogate framework, we have introduced the CEP surface and the marginal CEP curve as appropriate estimands for measuring the predictive capacity of a candidate surrogate. We developed estimation and testing methods under case-cohort sampling from a single large clinical trial (or multiple similar trials); such inferences apply for measuring surrogate predictiveness for the same or similar setting as the trial. The inferences do not form an empirical basis for bridging information about clinical efficacy to a new setting not represented in the trial(s) (e.g., to a new human population or treatment formulation); for this additional experiments (such as mechanistic studies and studies that deliberately manipulate the biomarker) and metaanalysis of heterogeneous studies are needed.
Because the definition of the CEP surface involves unobservable potential outcomes, strong untestable assumptions may be needed to identify it, possibly precluding its reliable estimation. The estimation method we developed requires A1-A3, a reasonably good model predicting S from baseline covariates X and W in treatment arm 1, and models for risk (z) (s 1 , c, x, w) or its marginal counterpart risk (z) (s 1 , x, w), for z = 0, 1. A1-A2 are standard in blinded randomized trials. A1 (SUTVA) is potentially dubious in the infectious disease setting where dependent happenings are possible (Halloran and Struchiner, 1995) , but should approximately hold in trials with a small study population relative to the total population of at risk individuals. A3 can be assessed by testing H x 0 : Pr (V = 1 | Z = 1, X = x) = Pr (V = 1 | Z = 0, X = x) at each of multiple fixed baseline covariate levels x, where rejecting H x 0 for any x rejects A3. It is difficult to fully verify A3, however, due to the curse of dimensionality. The method is expected to be robust to violations of A3 if the vast majority of clinical events happen after the biomarker measurement time. Otherwise it will be important to extend the methods to facilitate sensitivity analyses to departures from A3.
Models for the conditional distribution of S given X and W can be directly checked using arm Z = 1 data, and under A1-A3 models for risk (1) (s 1 , c, x, w) can be tested. The model for risk (0) (s 1 , c, x, w) specified by A4-P or A4-NP is not testable. However, with extra data collection Follmann's (2006) "closeout placebo vaccination" approach would provide one way to test it. Given the challenge in verifying this assumption, sensitivity analysis and the use of multiple surrogate evaluation approaches is warranted.
Within the principal surrogate framework considered here, internal validity of the putative surrogate can be checked by comparing the estimated overall clinical treatment effect, CE ≡ h( Pr(Y (1) = 1), Pr(Y (0) = 1)), to the CE predicted from the biomarker. Under A1-A3 and case CB, CE can be predicted by Pred(CE) = CEP risk (s 1 , c) dF (1) (s 1 ), which averages the predicted clinical treatment effect over the distribution of observed marker values of subjects assigned arm Z = 1. Furthermore, the estimated CEP curve can be used to check projective validity, that is, the utility of S for bridging efficacy predictions across populations. For example, suppose treatments Z = 1 and Z = 0 are compared within two subroups of a large trial. The CEP surface can be estimated from subgroup 1 data, and Pred(CE) calculated by estimating F (1) (·) from the observed biomarker values S of subgroup 2 subjects in arm Z = 1. Then projective validity would be supported by Pred(CE) near CE for subgroup 2.
The estimands and estimation techniques developed here for a binary clinical endpoint Y also apply for a quantitative clinical endpoint Y, with all expressions Pr(Y (Z) = 1 | ·) replaced with E(Y (Z) | ·). In either case the CEP estimands describe how the average or population level causal effect on Y depends on the causal effect on S.
Supplementary Materials
Web Appendices referenced in Sections 2.1, 3.1, 3.2, and 4.3 are available under the Paper Information link at the Biometrics website http://www.biometrics.tibs.org. R code for the nonparametric method is also available at the Biometrics website.
